

South Carolina  
Department of Health and Human Services  
Post Office Box 8206  
Columbia, South Carolina 29202-8206

Pharmacy and Therapeutics (P&T) Committee Meeting  
May 4, 2011  
MINUTES

1. Call To Order

A meeting of the P&T Committee convened at 4:00 p.m. on Wednesday, May 4, 2011.

2. Welcome

Debbie Tapley, R.Ph. called the meeting to order and welcomed members, guests, and staff members.

Debbie Tapley opened the meeting by stating that the P&T Committee meetings are held in compliance with the Freedom of Information Act's (FOIA) mandate that the public is notified when the public's business is being done, and that furthermore, the public has been notified that this facility is accessible to individuals with disabilities, and special accommodations could have been provided if requested in advance.

3. Committee Members Present:

Greg Browning, M.D.  
Kelly Jones, Pharm.D.  
Jim Lindsay, M.D.

Sara Lindsey, M.D.  
Thomas Phillips, RPh  
Tan Platt, M.D.

Debbie Tapley, RPh  
Ed Vess, RPh

DHHS Staff Present:

Tony Keck, Medicaid Director  
James M Assey, R.Ph.  
Deidra Singleton, J.D.  
Vicki Johnson, J.D.  
Valeria Williams

Magellan Medicaid Administration:

Mary Roberts, R.Ph.

Pharmaceutical Industry Speakers

4. Discussion Topics

A. Committee Meeting Minutes, Wednesday, November 3, 2010.

The draft minutes from the previous P&T Committee meeting were emailed to the members so that they could review the document prior to the meeting. The minutes were approved unanimously.

B. SC DHHS Presentation

Director Anthony Keck was introduced to the group and discussed his goals for the future of Medicaid to purchase quality healthcare in order to save long term costs and promote better health.

C. Public Comment

The rules for public comment were outlined. Debbie Tapley instructed the speakers that presentations would be limited to three minutes. The Committee members' meeting packets included the speakers' curriculum vitae and signed disclosure declaration forms that were submitted prior to the meeting. The following speakers (in order of appearance) discussed the drugs listed below.

Company	Speaker	Drug
Bristol-Myers	James Simples, PhD	Kombliglyze XR
Merck & Co.	Vicki Star, MD	Januvia/Janumet Saphris
Astra Zeneca	Jamie Street. MD	Seroquel XR
Bristol-Myers	Rachel Self, PhD	Abilify
Novartis	Dean Jones, PhD	Fanapt
Eli Lilly	Kirsten Mar, PharmD	Zyprexa
Forest	Aroon Datta, MSc	Lexapro
N/A	Jennifer Pender MD	General Testimony
N/A	Bill Lindsey	General Testimony

D. Drug Classes for Review

Mary Roberts, R.Ph. led the discussion for the following drug classes:

- DPP-4 Inhibitors and Combinations
- Proton Pump Inhibitors
- Non-Ergot Dopamine Agonists
- Bladder Relaxants
- Selective Serotonin Reuptake Inhibitors
- Atypical Antipsychotics

The chart below represents the recommendations from the P & T Committee:

DPP-4 Inhibitors and Combinations	
Preferred	Non-Preferred
Janumet® Januvia® Kombiglyze XR® Onglyza®	
Proton Pump Inhibitors	
Preferred	Non-Preferred
Nexium® Omeprazole Pantoprazole	Aciphex® Dexilant® Lansoprazole Nexium® Suspension Omeprazole/Sodium Bicarb Prevacid® Prilosec® Protonix® Zegerid®
Non-Ergot Dopamine Agonists	
Preferred	Non-Preferred
Pramipexole Ropinirole	Mirapex® ER Mirapex® Requip® XL
Bladder Relaxants	
Preferred	Non-Preferred
Detrol LA® Oxybutynin Oxybutynin ER Oxytrol® (Transdermal) Toviaz® Vesicare®	Detrol® Ditropan XL® Enablex® Gelnique® Trospium Sanctura XR®
Selective Serotonin Reuptake Inhibitors	
Preferred	Non-Preferred
Citalopram Fluoxetine Fluvoxamine Paroxetine Sertraline	Fluoxetine Weekly Lexapro® Luvox CR® Paroxetine CR Paxil® Suspension Pexeva®

Atypical Antipsychotics	
Preferred	Non-Preferred
Clozapine	Abilify®
Fanapt® Fazaclo®	Invega®
Geodon®	Latuda®
Risperidone	Symbyax®
Saphris®	Zyprexa®
Seroquel® IR & XR	

5. Old Business

Mary Roberts presented requested information from the last meeting. OTC utilization and an update on rosiglitazone utilization were presented to the group.

6. New Business

7. Resolved Items

Recommendations regarding PDL status for drugs in the following classes were approved for submission to DHHS.

- DPP-4 Inhibitors and Combinations
- Proton Pump Inhibitors
- Non-Ergot Dopamine Agonists
- Bladder Relaxants
- Selective Serotonin Reuptake Inhibitors
- Atypical Antipsychotics

8. Closing Comments

The next meeting will be held on Wednesday, August 3, 2011 at 4:00 p.m. at the same location.

9. Adjournment

The meeting adjourned at 6:35p.m.